3/27
07:25 am
athe
Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy
Low
Report
Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy
2/10
07:25 am
athe
Alterity Therapeutics Raises A$40.0 million in Placement
Low
Report
Alterity Therapeutics Raises A$40.0 million in Placement
2/3
07:10 am
athe
Alterity Therapeutics Limited (NASDAQ: ATHE) was downgraded by analysts at Benchmark Co. from a "speculative buy" rating to a "hold" rating.
Medium
Report
Alterity Therapeutics Limited (NASDAQ: ATHE) was downgraded by analysts at Benchmark Co. from a "speculative buy" rating to a "hold" rating.
1/30
05:52 pm
athe
Alterity Therapeutics Limited (NASDAQ: ATHE) had its price target raised by analysts at Maxim Group from $8.00 to $12.00. They now have a "buy" rating on the stock.
Medium
Report
Alterity Therapeutics Limited (NASDAQ: ATHE) had its price target raised by analysts at Maxim Group from $8.00 to $12.00. They now have a "buy" rating on the stock.
1/30
07:35 am
athe
Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy
Medium
Report
Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy
1/24
07:35 am
athe
Appendix 4C – Q2 FY25 Quarterly Cash Flow Report
High
Report
Appendix 4C – Q2 FY25 Quarterly Cash Flow Report
1/9
07:25 am
athe
Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones
Low
Report
Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones